跳转至内容
Merck

Y0001301

诺氟沙星

European Pharmacopoeia (EP) Reference Standard

别名:

1-乙基-6-氟-1,4-二氢-4-氧代-7-(1-哌嗪基)-3-喹啉羧酸, 1-乙基-6-氟-1,4-二氢-4-氧代-7-哌嗪-3-喹啉羧酸

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C16H18FN3O3
CAS号:
分子量:
319.33
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

norfloxacin

製造商/商標名

EDQM

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

CCN1C=C(C(O)=O)C(=O)c2cc(F)c(cc12)N3CCNCC3

InChI

1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)

InChI 密鑰

OGJPXUAPXNRGGI-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Norfloxacin for peak identification EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

诺氟沙星通过干扰 ATP 诱导转换 DNA 与 DNA 旋转酶(拓扑异构酶)复合物的结构转换而阻断 DNA 复制。
操作方式:抑制细菌 DNA 复制
抗菌谱:革兰氏阴性菌; 对革兰氏阳性菌效果较差

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Eye Irrit. 2

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 2


从最新的版本中选择一种:

分析证书(COA)

Lot/Batch Number

抱歉,我们目前尚未线上提供该产品的COA。

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

D E Nix et al.
Clinical pharmacy, 6(2), 105-117 (1987-02-01)
The chemistry, mechanism of action, antimicrobial spectrum, pharmacokinetics, clinical efficacy, adverse effects, and dosage and administration of ciprofloxacin and norfloxacin are reviewed, and mechanisms of antimicrobial resistance and drug and laboratory interactions are described. Norfloxacin is the first antimicrobial in
J S Wolfson et al.
Annals of internal medicine, 108(2), 238-251 (1988-02-01)
Norfloxacin is an oral fluoroquinolone antimicrobial agent recently released for the treatment of uncomplicated and complicated urinary tract infections. The drug antagonizes DNA gyrase, an enzyme essential for bacterial DNA replication. Norfloxacin is more potent and broader in spectrum than
Jessica M A Blair et al.
The Journal of antimicrobial chemotherapy, 70(2), 424-431 (2014-10-08)
Enterobacteriaceae have multiple efflux pumps that confer intrinsic resistance to antibiotics. AcrB mediates clinically relevant multidrug resistance and is required for virulence and biofilm formation, making it an attractive target for the design of inhibitors. The aim of this study
Bacterial resistance to norfloxacin and other newer quinolones: pattern and prospects.
D R Nalin
European journal of cancer & clinical oncology, 24 Suppl 1, S55-S61 (1988-01-01)
Ying-Jun Zhou et al.
FEMS microbiology letters, 355(2), 124-130 (2014-05-13)
The antimicrobial activity of one 3-hydroxypyridin-4-one (HPO) hexadentate (1) and three HPO hexadentate-based dendrimeric chelators (2-4) was evaluated. They were found to exhibit marked inhibitory effect on the growth of two Gram-positive bacteria and two Gram-negative bacteria. The combination treatment

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门